Printer Friendly

Trigeminal Neuralgia, Glossopharyngeal Neuralgia, and Myofascial Pain Dysfunction Syndrome: An Update.

1. Introduction

Neuralgia is known as pain that occurs in the nerve pathways. Usually, neuralgia is not a sickness but a symptom of an injury or a disorder. Pain in the maxillofacial region exhibits medical, dental, social, and psychological burdens. Maxillofacial pain originates from many sole target tissues such as the meninges, cornea, tooth pulp, oral/nasal mucosa, and temporomandibular joint, thus showing numerous unique physiological features associated with the spinal nociceptive system [1]. Maxillofacial pain disorders cover a major remarkable and extensive part of neurological disorders and collectively have a high occurrence rate and an often overwhelming influence on the quality of life [2].

Although there are several common features of pain transduction and processing between the trigeminal and spinal nerve systems, numerous characteristic features in the peripheral and central components of the trigeminal pain system exist. Trigeminal neuralgia (TN) is the incidence of uncontrollable and electrical stun-like pain with a trigger zone, while glossopharyngeal neuralgia (GPN) is considered as pain in the oropharyngeal area throughout the mandibular actions, mainly deglutition [3, 4]. Myofascial pain dysfunction syndrome (MPDS) is categorized by extensive pain, decreased pain relief, sleep disruption, exhaustion, psychosomatic distress, and chronic headache. Patients with MPDS are identified based on the presence of numerous tender points [5]. Consequently, current basic and clinical studies that focus on acute and chronic maxillofacial pain need to realize the unique features of the pain system and to advance and assess better treatments for orofacial pain.

The most important obstruction of enhanced patient care and translational research is the absence of approved diagnostic criteria [6]. The intricate innervation and function of facial region assemblies make the diagnosis of facial pain and its treatment very problematic and frustrating [7]. Patients with long-lasting facial pain should be cautiously reevaluated and clinically examined even after getting multiple treatments. The situation is compounded when neuralgia, ear nose and throat (ENT) diseases, dental pain, myofascial pain syndromes, tumors, temporomandibular disorders (TMD), neurovascular pain, or psychiatric diseases commonly present with covering signs and symptoms. In addition, referred, severe, and acute pain frequently makes the diagnosis more challenging [7, 8]. However, most neuralgia conditions demonstrate similar clinical features. Therefore, sequential clinical examinations with additional laboratory diagnoses are essential for the proper treatment and management of such conditions [9].

An effective evidence-based management of neuralgic pain requires a thorough appreciation of the underlying mechanism of pain. In this review, we describe the updated knowledge on the pathophysiology, clinical features, diagnostic criteria, and management of TN, GPN, and MPDS.

2. Trigeminal Neuralgia

Trigeminal neuralgia is a unilateral disorder highlighted by electric stun-like neuropathic pain near the distribution of the trigeminal nerves with sudden onset and termination. It is defined as a syndrome that is characterized by paroxysmal facial pain. According to Loh et al. (1998), the affliction site ratio was observed as 1.4 (right): 1 (left) of the facial area [10]. The characteristics of TN include sudden, severe, periodic, stabbing, lancinating, lightning-like, and shock-like pain attacks that are usually one-sided in the 2nd and/or 3rd trigeminal branch [11-13]. TN is one of the most common neurological pains involving the orofacial region, which generally has the most intensive type of pain [4, 14, 15]. It typically affects the elderly (1 in 25,000 of the population), with the most frequently reported cause being neurovascular compression [16-18]. From an etiological aspect, TN is classified as classic or primary or idiopathic and symptomatic or secondary. Classic or primary TN appears with no clear cause. Symptomatic or secondary TN occurs with the presence of intracranial lesions such as a tumor, infarction, and multiple sclerosis (MS). From a symptomatic aspect, TN is classified as "typical" in the presence of paroxysmal pain alone and "atypical" when the paroxysmal pain is associated with constant pain [19].

Pain in 95% of the TN cases is almost unilateral, commonly affecting the mandibular and maxillary divisions [13]. According to Loh et al. (1998), there was a greater contribution of the mandibular branch of the trigeminal nerve than the maxillary branch in TN patients (n = 44) [10]. An attack of TN is typically originated by a slight mucocutaneous incentive in the region of the affected trigeminal nerve also known as a trigger point [18,19]. The diagnosis of TN is based on the typical case history of episodic electric pain in the supply of the trigeminal nerve [20]. However, the diagnosis and management of TN require a group of experts consisting of neurologists, anesthesiologists, neurosurgeons, neuroradiologists, oral and maxillofacial surgeons, and dentists [21,22].

2.1. Epidemiology. The prevalence of TN has been estimated at 107.5 males and 200.2 females per 1 million populations [23]. The incidence rate of TN was 4.3 per 100,000 in the US population, with the age-adjusted rate for females being significantly higher than that for males [24]. The predictable frequency of TN is approximately 4-12.5/100,000 people annually, with increasing occurrence based on stage [25]. Because age is a primary risk factor, symptom manifestation is more likely after the age of 50 years [26]. The topmost inception of TN occurs between the ages of 50 and 70 years, but it can happen even at a younger age. A study reported the usual age of sign onset at 19.6 [+ or -] 3.4 years [27]. The most widely recognized age group was 51 to 60 years (36.90%), followed by 61 to 70 years (23.68%) and 41 to 50 years (17.35%) [28]. It is unusual in individuals older than 30 years, with only 1% of cases in those more youthful than 20 years of age [29,30]. The annual occurrence in females is approximately 5.9/100,000 cases per females, while it is approximately 3.4/100,000 cases per males [25, 31]. The female-to-male proportion of TN was 3:2 [32]. TN is more common among females (62%) than among males (38%), with a female-to-male ratio of 1.6: 1 [33]. Thus, females have a higher risk of having TN than males, and the risk again increases with age [30].

In addition, a retrospective study of TN patients in Singapore and Malaysia revealed that the age of onset fluctuates from 24 to 89 years with a mean age of 54.9 years. The ultimate occurrence was in the 6th (29.5%) and 7th (27.3%) decades of life, followed by the 5th decade (13.6%). The fourth and eighth decades had similar incidences (11.4%). This was followed by the third (4.5%) and ninth (2.3%) decades. With respect to sexual orientation, females account for 63.7% of the patients, with a ratio of 1.75: 1.00. The distribution of TN in multiethnic populations was 68.2% among the Chinese, followed by 13.6% and 11.4% in Malays and Indians, respectively. The remaining distribution was solitary Japanese and two Eurasians [10].

Other than the age and gender, multiple sclerosis (MS) is a well-known risk factor to TN [10,27]. MS has been reported in 2 to 4% of patients with TN where demyelination is also present [24]. The reported prevalence of TN in the MS population was between 1.0% and 6.3% [34, 35]. In addition, approximately 4% of MS patients have a lifetime risk to have TN, with no significant difference observed among the different forms of MS [36]. Approximately 5% of idiopathic TN cases have been reported to have a family history [33]. Hence, older females, MS, and family history are important risk factors for TN.

2.2. Pathophysiology. TN occurs due to the specific abnormalities of the trigeminal nerve in the trigeminal root or ganglion. The pathophysiological characteristics of classic or idiopathic TN are identified with the pressure of the trigeminal nerve root by a vein at or nearby the root passage zone [17, 37, 38]. An artery crossing the nerve can provoke further displacement [39], which can lead to damage and injury of the trigeminal nerve. The damage tends to be localized and is specifically related to the vascular contact [40, 41]. The damaged nerves cause pain via several mechanisms, including the hyperexcitability of the demyelinated nerve fibers, ectopic impulse discharge, spontaneous and triggered after discharge, cross excitation between sensory channels, deafferentation, impaired segmental inhibition, and emphatic transmission [38, 40-43]. The vascular pressure of the trigeminal nerve root is associated with the focal loss of myelin and the close juxtaposition of the demyelinated axons with few mediating astrocytic processes [40].

Symptomatic or secondary TN occurs due to intracranial lesions such as a tumor, infarction, and MS [19, 44]. Intracranial tumors in the presence of aneurysms, angiomas, or vascular malformation are among other causes of TN [45,46] that may occur by either direct tumoral compression or the wrapping of the trigeminal nerve root [47, 48]. Tumor occurrence has been reported to be more common among TN patients aged less than 39 years than among those older than 40 years [49]. Approximately 2 to 4% of MS has been reported to occur in TN patients [24] as well.

2.3. Clinical Manifestation. The hallmark of TN includes recurrent attacks of lancinating pain in the trigeminal nerve [50]. The attacks typically last just seconds, yet they may be repeated over and again inside a brief time frame. Approximately 79% of the pain experienced is intermittent, while 21% of pain is continuous [13]. The nature of pain is sporadic, sudden, and often like an electric shock, enduring from a few moments to a few minutes [27]. In fact, TN has been reported to be a relatively common pain condition, occurring more commonly on the right side (72.63%) than on the left side (27.37%) with a ratio of 2.6: 1.0 [30, 51] and mainly affecting the mandibular division [10, 30]. The communal outlying nerve involved is infraorbital with various patients presented with sensible pain [30].

The brief paroxysms pain in TN is restricted to the facial conveyance of the trigeminal nerve and can be triggered by stimuli to sensory endings in the trigeminal receptive area [52]. The triggering stimuli include simple actions such as talking, swallowing, laughing, washing, wind-blowing, shaving, mouth opening, touching, and chewing. Nevertheless, the presence of these triggering stimuli may cause the patients to circumvent any stimulus on the face or mouth. Most patients respond to different strengths of the aggravating stimulus and react to more than a single triggering stimulus [53].

2.4. Diagnostic Criteria. The diagnosis of TN basically relies on a patient's description of pathognomonic pain occurrences [54]. The primary

diagnostic tools are MRI (magnetic resonance imaging) and CT (computed tomography), since there is no specific laboratory test available (Table 4). Therefore, patients' signs and symptoms are key important factors in making the diagnosis (Figure 1).

TN is generally idiopathic [55]; however, it might likewise emerge optional to different conditions, including the intracranial space involving lesions and multiple sclerosis [35, 56, 57]. The International Association for the Study of Pain (IASP) and International Headache Society (IHS) has recommended their own indicative criteria for TN [58, 59]. The IASP has defined the TN as a sudden, normally one-sided, extremely brief cutting intermittent pain in the dissemination of at least one branch of the fifth cranial nerve. On the other hand, the IHS defines TN as an excruciating one-sided distress of the face, described by brief electric stun-like pain restricted to the circulation of at least one division of the trigeminal nerve. Pain is usually induced by insignificant stimuli, which include smoking, sneezing, and brushing the teeth, all of which often regularly occur impulsively. Little zones in the nasolabial fold and chin might be prone to the precipitation of pain that may remit for variable periods [58].

According to Eller et al. (2005), TN is defined and classified into seven types: (i) TN1: idiopathic, sharp, shooting, electrical shock-like, and episodic pain; (ii) TN2: idiopathic, aching, throbbing, burning, and more than 50% constant pain; (iii) TN3: trigeminal neuropathic pain and accidental harm to the trigeminal nerve from injury or surgery (facial trauma; oral operation; ear, nose, and throat operation; skull base operation; posterior fossa operation; or stroke); (iv) TN4: trigeminal deafferentation pain and intentional injury to the trigeminal nerve (gangliolysis, nucleotomy, neurectomy, tractotomy, rhizotomy, or other denervating procedures); (v) TN5: symptomatic, associated with MS; (vi) TN6: postherpetic because of a flare-up of facial herpes zoster; and (vii) TN7: atypical facial pain and facial pain auxiliary to a somatoform pain issue, requiring mental testing for indicative diagnostic affirmation [32].

2.5. Treatment and Management. Table 1 presents various pharmacological agents and available treatment options based on surgical procedures. Both methods are effective and widely used [60-62]. Usually, TN patients are first treated with pharmacological agents. The pain can be readily managed with medication in approximately 80% of patients [63]. However, if the pain is not effectively relieved by medications or there is medication intolerance due to toxicity or allergic reactions, surgical treatment becomes an option.

In standard practice, the first-line treatment is carbamazepine, which can relieve most of the observed symptoms [22, 64-66]. Other drugs, including oxcarbazepine [67], phenytoin [68, 69], baclofen [70, 71], lamotrigine [72, 73], gabapentin [74, 75], and sodium valproate [76, 77], are also efficient in reducing the signs-symptoms of TN in most patients. Sometimes, some of the drugs are taken with carbamazepine as an adjuvant for the synergistic effects in relieving the TN symptoms [78, 79]. The decreasing relief provided by carbamazepine or other drugs with continual use as well as unacceptable side effect profiles may necessitate the discontinuation of therapy. In fact, it has been reported that approximately 50% of patients eventually require an operation to relieve pain [25]. Research has indicated that there is no significant influence of age, sex, ethnicity, or the side of the face on the decision of the medication regimen and the length of treatment for pain control [79].

When drugs no longer offer pain relief, surgical intervention is preferred. The objective of surgery procedures is to prevent the blood vessel from squeezing the trigeminal nerve or injuring the trigeminal nerve. Several surgical approaches used to relieve the pain due to TN include neurectomy of trigeminal nerve branches outside the skull, percutaneous radiofrequency thermal rhizotomy, percutaneous ablation that creates trigeminal nerve or trigeminal ganglion lesions with heat [80-82], percutaneous retrogasserian glycerol rhizotomy, injection of glycerol into the trigeminal cistern [62, 83, 84], physical compression, trigeminal ganglion balloon microcompression [85], alcohol injections [57, 86], botulinum toxin injection [87, 88], cryotherapy [89, 90], and gamma-knife radiosurgery (GKRS) [91]. These procedures are intended to alleviate the symptoms of TN by relieving nerve compression at some point along its course. Hereafter, the management of TN is dependent on a fast, correct diagnosis, prompt, and effective treatment because the symptoms can be very severe.

2.6. Complications. Many drugs used in the treatment and management of TN are associated with several side-effects. Nevertheless, most of the effects can be tolerated and immediate drug discontinuation is conducted when the common pain tolerance level is exceeded. In addition, some of the surgical procedures may contribute to some complications such as microvascular decompression (MVD) which is able to relieve an abnormal compression of an artery to the trigeminal nerve. Although it is generally successful, achieving 70-90% pain control and less than 1% of the mortality risk [92], the procedure may lead to hearing loss which is associated with a refutation injury of cranial nerve VIII [93]. Nevertheless, the complications were less common following an intraoperative monitoring of the brainstem evoked response.

The rate of ipsilateral hearing loss was 3% (previous 1980) and 1% thereafter (p = 0.008). Radiosurgery, which can increase the pain control rate up to 83%, is effective in treating TN [91]. Its complication rate is only 6% for facial paresthesia and 4% for hypoesthesia [94]. An immediate complete loss of vision in one eye after trigeminal radiofrequency rhizotomy was reported in three patients due to acute traumatic optic neuropathy [95]. Moreover, there were patients who have masseter weakness and paralysis, keratitis and transient paralysis of cranial nerves III and VI, diminished corneal reflex, dysesthesia, and anesthesia dolorosa [96]. Nevertheless, MVD remains the best choice and a useful alternative to carbamazepine in the treatment of TN (Table 1).

3. Myofascial Pain Dysfunction Syndrome

Myofascial pain dysfunction syndrome (MPDS) is known as a psychophysiological disease, which is associated with muscular structure--in particular, the muscle of mastication [97]. MPDS is a commonly observed phenomenon in the medical, dental, and psychological sectors. MPDS is also termed myalgia, myofasciitis, myogelosis, myofascial pain, fibromyalgia, myofibrositis, and myofascial pain syndrome (MPS). When it is mainly associated with temporomandibular join dysfunction, it is termed as myofascial pain dysfunction syndrome [98-100]. Although the terms myofascial and musculoskeletal pain are used frequently and alternately, they are different. Basically, musculoskeletal pain encompasses almost all types of pain observed at the muscular level, while myofascial pain indicates a specific syndrome caused by the presence of trigger points (TrPs) within the muscles or their fascia [101].

The following factors play a significant role in the etiology of MPDS: (1) trauma, which is divided into macro- and microtraumas; the former includes contusions, sprains, and strains, all of which may result in acute MPDS; the latter, however, has a slower onset. Chronic repetitive overloading or the further overuse of muscles may cause fatigue; (2) mechanical causes, which can be a result of internal factors such as having incorrect postures or external factors such as having poor ergonomics, especially at work; (3) degenerative causes due to aging where the degeneration of bones and joints, loss of myofascial flexibility, and arthritis can occur; (4) nerve root compression, which may cause irritation and lead to sensitization to the spinal segment; (5) dental causes, which include occlusal disharmony; (6) faulty dentures; (7) dental extraction; and (8) other factors.

According to Svensson and Graven-Nielsen, 2001 [102], MPDS is defined as a stress-related disorder. It is assumed that increased muscle tension, commonly combined with the existence of some parafunctional habits (such as clenching or grinding of teeth), results in muscle fatigue and spasms highly responsible for the pain experienced as well as the mandibular dysfunction. However, it may also occur as a consequence of muscular overextension, muscle overcontraction or trauma in some rare cases [103,104].

Myofascial pain syndrome is defined as a disorder that is associated with pain arising from TrPs within the myofascial structures, the pain appearing either locally or distant from the affected region. On the other hand, TrPs are sensitive areas in a muscle that continuously (or upon compression) cause pain to a distant region [99,105]. Alternatively, it can also be described as a confined tender area in a firm band of skeletal muscle, tendon, or ligament. These points can arise in any skeletal muscle, occurring most repeatedly in the head and neck, shoulders, and lower back [99].

3.1. Epidemiology. MPDS appears with muscular pain and regional symptoms [106,107] with a 30% percent occurrence, thus contributing to considerable disability and inability to work [108, 109]. It has been reported that, in the American population, approximately 44 million people have myofascial pain-associated problems [110]. A statement from specialized clinics for head and neck pain stated that 55% of cases are related to myofascial etiology, while 95% of cases have myofascial pain [111]. According to the same study (n = 164), 55% of patients diagnosed with myofascial pain also have chronic head and neck pain for a minimum of six months [112]. A Danish researcher reported the existence of myofascial pain in 37% of men and 65% of women within a randomly selected population (n = 1504) aged between 30 and 60 years [113]. The Myofascial Pain Management Center at the University of Miami School of Medicine conducted a study in an American population (n = 283) and reported that 85% of the cases primarily presented with MFP syndrome [114]. Another study stated that 74% of the patients had pain due to a primary cause (such as mechanical cause), while 93% complained of pain during the diagnosis. The data indicate that a high proportion of patients are unaware of their disease, with 74% of patients attending the clinic with pain that is purported to be caused by either mechanical injury or trauma [112].

Another study reported that females tend to experience a higher recurrence rate of MPDS than males, with the male : female proportion ranging from 3 : 1 to 5 : 1 in various reports [115]. The age group showing the highest incidence was the 20- to 40-year age group, although children can also have MPD syndrome [116]. The mean prevalence of pain among middle-aged to advanced-age individuals (30-60 years) is 37% for males and 65% for females. In advanced-aged patients (>65 years), the prevalence can be as high as 85%. As a result, based on the demographics of aging, MPS can most likely convert to one of the major problems in the general population in the future [101].

3.2. Pathophysiology. The origin of TrPs in MFP syndrome is still unknown, although there has been significant progress in the identification of the features of TrPs [117, 118]. Precipitating factors of MFP (such as nerve root compression and degenerative cause) have been hypothesized to lead to the discharge of acetylcholine at motor end plates [119], thus causing muscle fiber contractions. The release of vascular and neuroactive substances causes local ischemia and also aggravates muscular pain. Further acetylcholine discharge can propagate the muscle pain and spasm. After a prolonged period of time, local muscle fibrosis can occur [119,120]. The myofascial trigger point (MTrP) contains a neurovascular bundle that consists of motor nerve endings and groups III and IV nociceptive sensory afferent nerve endings [121,122]. Triggering the nerve can lead to the sensory and motor phenomena. In sensory phenomena, examined the nociceptive process in myofascial TrP pain in chronic tension-type headaches with 40 cases compared with 40 healthy controls. The pressure in MTrP showed a linear relationship with incremental pain, while the normal muscle tended to show a nonlinear relationship. Some mechanisms in the spinal cord that are associated with dysfunctional endplates in response to sensitized sensory nerve fibers may also be involved. The linear pattern of pain indicates that referred pain may occur in response to stimulation of MTrP compared with the normal muscle [123]. On the other hand, in motor phenomena, pathophysiological marker-needle electromyography (EMG) activity has been identified within the 1 to 2 mm nidus of MTrP. In 1986, Laskin and Block hypothesized that the source of electrical activity was intrafusal fibers inside the muscle spindle [103]. However, Greene proposed a standard hypothesis about dysfunctional motor endplates in 2001. According to them, such electrical activity is demonstrated in the endplate zone outside of MTrP [97].

3.3. Clinical Manifestation. MPDS is characterized by a dull, aching, radiating pain and is more acute in jaw movement (Figure 2). In the case of mandibular dysfunction, MPDS causes limitation in mouth opening [124, 125]. Almost 70% of patients complain of pain and tenderness around their temporomandibular joints. Some patients also reported the presence of a clicking sound or cracking noises in the temporomandibular joint (TMJ) [124]. MPDS usually involves only the face unilaterally. Frequent headache is also a common complaint (23% of cases). Only tension headaches may be directly or indirectly associated with this syndrome. In addition, a patient may also complain of diminished hearing, tinnitus, burning tongue, and neuralgic pains. MPDS also leads to some functional disorders and may cause organic variations in the temporomandibular joint as well as in masticatory muscles [103,125]. Usually, the patient shows pain in the trigger area when approximately 3 kg of pressure is applied. The fibers show the local twitch response (LTR) during plucking palpation inside the band of muscle [107].

3.4. Diagnostic Criteria. Myofascial pain syndrome is associated with MTrPs and can be reproduced by firm palpation over the trigger zone. The diagnostic features for myofascial trigger points include the following:

(i) Upon palpation of the muscle, a focal point of tenderness may be found.

(ii) Trigger point palpation leads to a reproduction of the pain.

(iii) There is a "taut band" in adjacent muscle.

(iv) There is restriction of muscle movement.

(v) It may appear with pseudo-weakness of the muscle fiber.

(vi) Paresthesia occurs over the muscle area.

The diagnosis of MFP syndrome may be a challenge because it shows some complex clinical characteristics. Most patients tend to show some tenderness (67%) of the elevator muscles during palpation. Nearly 40% of the patients' complain of pain on chewing. Thus, 30% have significant myalgia with bruxism [126]. Sometimes, the patients may also complain of sleep disturbance because the sleeping position may act as an aggravating factor to the pain caused by MTrP [107].

Arthrography is a useful procedure for the diagnosis of MPDS when the TMJ is involved. Radiographic interpretations of the head and neck region, CT scans and scintigraphy, can also help to establish the concluding diagnosis. In this case, MRI is indicated to allow better view of the condyle and disc position of TMJ specifically. Sometimes laboratory tests such as a complete blood count (in the case of suspected infection), serum calcium, phosphorus, and alkaline phosphatase (for bone disorder) need to be investigated. Serum uric acid (for gout), serum creatinine, and phosphokinase levels help as useful indicators of muscular disorders. If rheumatoid arthritis is suspected, the electrolyte sedimentation rate (ESR) and rheumatoid factors should be investigated. Additionally, electromyography can be used to assess muscle function and fatigue. However, psychologic evaluation and psychometric testing may also help in the diagnosis [127].

3.5. Treatment and Management. Patient counseling regarding the disease is very important. Usually, it is often difficult for patients to accept a psychophysiologic explanation for their diseases. Connecting the symptoms to specific masticatory muscles can facilitate the determination of the actual cause of the type and location of pain. In cases of the involvement of the temporal muscle, patients may suffer where headache and jaw ache are common in the masseter and pterygoid muscles, showing discomfort during swallowing and earache associated with the lateral pterygoid muscle [128].

Normally, injection is the first treatment approach in the treatment of MPDS. An injection using dry needling and lidocaine anesthetic solution injection may be helpful in MPDS treatment. In 2010, Ay et al. [129] reported that using dry needling and lidocaine injection with stretching exercises may show a momentous role in the treatment of MFP syndrome. Besides, botulinum toxin injection has been reported to produce significant effects such as sudden pain reduction, especially when a saline injection is not effective [130-132]. Moreover, Gazi et al. (2010) compared the analgesic result of acupuncture (which is purported to help restore blood circulation) to TrPs injections (containing 0.25% bupivacaine administered twice weekly) with cyclobenzaprine chlorhydrate and sodium dipyrone on trigger points to prevent the recurrence of MFP symptoms. The results showed comparable pain liberation and progress in the quality of life at 4 weeks [133]. Additionally, therapeutic ultrasound is a new treatment strategy for MFP syndrome. Because it is a noninvasive procedure, it is valuable in the treatment of deeper muscle. Manual therapeutic techniques are not sufficient for the assessment of deep muscle [134]. Other approaches have been used in the treatment and management of MPDS including psychotherapy [135, 136], home therapies [137], medications [138, 139], and dental management [140, 141]. Sequential treatment is needed to manage such pain syndrome (Table 2).

3.6. Complications. In the case of a misdiagnosis, chronic pain syndrome and complex behavioral problems may result, leading to psychosocial problems. Most of the time, chronic pain may cause sleep disturbance where patients have trouble finding a comfortable sleeping position. Sometimes, posture changes during sleep may affect the disease, thus affecting the patients' sleep throughout the night [108].

4. Glossopharyngeal Neuralgia

Glossopharyngeal neuralgia (GPN) is a very sporadic condition related to hyperactivity of the glossopharyngeal nerve [142]. GPN is rare compared with TN. The pain affects the sensory areas corresponding to the glossopharyngeal neuralgia with a branch of sensory vagus nerves. GPN consists of spasmodic, momentary, and severe sharp pain in the posterior area of the throat, tonsillar fossa, base of the tongue, ear canal, and areas inferior to the angle of the mandible [143]. Generally, the pain persists for seconds to minutes and is often triggered by chewing, coughing, yawning, talking, and swallowing [144]. The prevalence of GPN is estimated to be approximately 0.8 per 100,000 populations in a year, indicating that it is less common than TN (4.7 cases per 100,00) [26]. GPN is usually represented by a painful condition on the left side of the body in females, whereas TN is more commonly observed on the right side [145].

GPN is a mixture of cranial nerves that have somatic sensory fibers from the oropharynx, mastoid, middle ear, and Eustachian tube, and posterior third of the tongue. The middle ear and mastoid have a sensory supply of glossopharyngeal nerve along with the tympanic branch or Jacobson's nerve [146]. It also receives special sensory fibers for taste as well as chemoreceptor and baroreceptor afferent input from the carotid body and carotid sinus. Stylopharyngeus muscles are supplied by the motor component, and the parotid gland is supplied by the parasympathetic secretomotor supply. The nerve of Hering is an important branch of the carotid sinus branch, which conveys chemoreceptor and baroreceptor information centrally for circulatory reflux function and may be accountable for the arrhythmogenicity of GPN [146,147].

GPN is classified according to HIS, based on the involved structural areas. The proposed classification of IHS is (1) classical GPN (occasional or episodic pain) and (2) symptomatic GPN (constant pain) [58]. The classification is based on the areas involved in otitis, that is, pain in (or around) the auricle or earlobe. On the other hand, for the oropharyngeal type, the pain is in and around the neck as well as the maxillofacial regions. Nevertheless, these areas significantly overlap with other cranial nerve-supplied areas [148].

GPN may be idiopathic with the absence of any obvious lesion. Most cases are mainly recognized as glossopharyngeal nerve compression triggered by a vessel at the root entry zone of the brainstem [148,149]. Idiopathic causes maybe vascular decompression and/or central pontine dysfunction. The secondary cause is a noticeable lesion that includes trauma (skull base fracture, penetrating injury), postradiation, neoplasm (skull base, cerebellopontine, brainstem, pharynx, tongue, tonsil, metastatic head, and neck tumors), infection (tonsillitis, pharyngitis, petrositis, arachnoiditis, para pharyngeal abscess, and tuberculosis), surgery (posttonsillectomy, postneck dissection, and postcraniotomy), vascular malformations (arteriovenous malformation, fusiform aneurisms, persistent hypoglossal artery, and dissection of the vertebral artery), demyelination (MS), and Eagle's syndrome as well as others which include direct carotid puncture, choroid plexus overgrowth, and hyperactive dysfunction syndrome. This type of GPN is usually accompanied with numbness or pain around the affected area [150].

4.1. Clinical Manifestation. There are paroxysmal attacks of facial pain, which last for seconds to minutes (Table 3). The characteristics of pain are unilateral sharp, stabbing, and severe shooting pain. The distribution of pain is persistent within the posterior part of the tongue, pharynx to inner angle of the lower jaw, and tonsillar fossa [151]. Pain occurs within a certain interval with most occurring after a long time, although some patients may experience it within a day [152,153].

The common trigger factors are swallowing, chewing, talking, coughing, yawning, lateral movement of the jaw, cleaning of the throat, tinnitus, sudden movement of the head, touching the periodontium, and touching the external surface of the ear. GPN is not attributed to other disorders but may be related to vascular malformation, oropharyngeal tumor, cerebellopontine angle masses, Chiari type I disorder, multiple sclerosis, or TN [144, 154-158]. GPN may be not found during an early screening or examination [159]. In fact, GPN is often confused with Jacobson's neuralgia during clinical examination [160].

4.2. Diagnostic Criteria. GPN shouldbe diagnosed by clinical examinations. Patients usually experience unilateral stabbing pain in the throat. The characteristics of pain and trigger factors are helpful to confirm GPN. Neuralgic pain is severe, episodic, and radiating for intervals compared with inflammatory pain. Inflammatory pain is persistent in nature, lasting for minutes. The distribution of pain should be determined to ascertain the involvement of the glossopharyngeal nerve or its association with other cranial nerves.

Classical GPN is mainly tympanic or posttonsillar pain with a history of surgery. Distribution of the trigger point is within the auricular, oropharyngeal area or can be triggered by swallowing, talking or hearing. Lignocaine (2%) or bupivacaine (0.5%) injection into the area close to the trigger point may be helpful for the identification of otologic pain. A complete history including trauma, radiotherapy, postsurgery, inflammation or pathology related to the oral and maxillofacial areas is useful to elucidate the cause of secondary GPN [161,162].

Laboratory test including erythrocyte sedimentation rate (ESR), serum chemistry, complete blood count, and antinuclear antibody is helpful to determine if infection, inflammation, and neoplastic malignancy occur. To determine if vascular compression, any malignancy, or hard tissue change has occurred, magnetic resonance angiography (MRA) and 3D CT-angiography, magnetic resonance imaging (MRI) can be useful [163,164]. These imaging techniques may help elucidate vascular compression by identifying the origin of the posterior inferior cerebellar artery since the posterior inferior cerebellar artery makes an upward loop and compresses the supraolivary fossette [165,166]. If the offending vessel is the anterior inferior cerebellar artery, the diagnosis of GPN is a challenge without surgery [167]. GPN secondary to Eagle's syndrome is identified by a panoramic radiograph [168].

4.3. Treatment and Management. Nonsurgical pharmacotherapy is the treatment of choice for most of the cases (Table 3). Failure of pharmacotherapy treatment, where the nerve is compressed, can prompt the physician to opt for surgery.

4.3.1. Nonsurgical Pharmacotherapy Approach. Carbamazepine, gabapentin, and pregabalin are first-line pharmacological treatments for GPN. Vitamin B12 and a low-dose selective serotonin reuptake inhibitor such as paroxetine (20-50 mg/day) or sertraline (50-200 mg/day) are also helpful. A long-term nonsteroidal anti-inflammatory drug is not recommended as long as the activity resulting in the inflammatory process can be reduced for treating GPN [169]. Opioids can be used, although they have been reported to provide no additional benefit [170]. If pain relief cannot be achieved, different medications such as baclofen and dextromethorphan can be used. The combination of two or multiple agents is effective with physical therapy or psychological treatment [171].

(1) Nerve Block. A glossopharyngeal nerve block is an excellent adjunct to the pharmacological treatment of GPN for rapid pain. A nerve block can be performed using a local anesthetic agent such as lignocaine (2%) and bupivacaine (0.5%) with or without steroids, ketamine, phenol, glycerol, and alcohol. A nerve block can be performed either as an intra- or extraoral approach. The extraoral approach is preferred, as it is simpler and more comfortable to the patient [172, 173]. Difficulties in deglutition and huskiness of voice can be an unwanted consequence of a glossopharyngeal nerve block. In addition, a bilateral nerve block can cause the paralysis of the vocal cord [172,174].

4.3.2. Surgical Approach. There are several surgical procedures offered such as direct surgical neurotomies or percutaneous radiofrequency thermal rhizotomy [173], direct sectioning of the nerve in the cerebellopontine angle [175], or open trigeminal tractotomy-nucleotomy or nucleus caudalis operations. The microvascular decompression (MVD) of vascular roots and the rhizotomy of nerve roots are the best options for surgical treatment. Vascular compression is well recovered by MVD. Normally, intracranial root section is widely considered when MVD is not possible [151, 176]. Through the improvement of microsurgical and anesthesiology techniques, MVD has been established as an effective and safe treatment option for drug-resistant GPN [175]. Over 76% of the cases showed improvement with MVD [162]. Extracranial neurotomy and percutaneous radiofrequency rhizotomy are not commonly performed, and their application is limited to drug-resistant GPN. Stylectomy is usually conducted for Eagle's syndrome after ruling out the primary cause of GPN [177, 178]. Pulsed radiofrequency neurolysis, gamma-knife surgery, and stereotactic radiosurgery have also shown beneficial effects in both idiopathic and secondary GPN [148,179].

5. Conclusion and Future Perspective

This review has outlined the current knowledge of the pathophysiology, diagnostic criteria, and treatment of three common neuralgic maxillofacial pain syndromes. TN, GPN, and MPDS can present with common signs. Hence, the appropriate use of definite diagnostic measures is significant to support the differential diagnosis. Severe and diffuse pain can obscure the diagnosis, possibly leading to an inappropriate finding or an incorrect diagnosis. Precise diagnostic criteria will facilitate clear diagnoses and the framing of good treatment plans for a proper therapeutic schedule. Various pharmacological and surgical treatment options have been used with varying success rates and morbidities. There is a need for further research into the management of neuralgic maxillofacial pain with appropriately designed treatment strategies. A multidisciplinary team is frequently essential for the diagnosis and management of many maxillofacial painful conditions.

TN:        Trigeminal neuralgia
MPDS:      Myofascial pain dysfunction syndrome
GPN:       Glossopharyngeal neuralgia
MS:        Multiple sclerosis
TrPs:      Trigger points
TMJ:       Temporomandibular joint
TMD:       Temporomandibular disorders
MRI:       Magnetic resonance imaging
CT scan:   Computed tomography scanning
IASP:      International Association for the Study of Pain
IHS:       International Headache Society
MVD:       Microvascular decompression.

Conflicts of Interest

The authors confirm that there are no conflicts of interest to declare.

Authors' Contributions

Mohammad Khan, Shamima Easmin Nishi, and Siti Nazihahasma Hassan are equal contributors.


The authors would like to acknowledge the Universiti Sains Malaysia (USM) Fellowships awarded to Mohammad Khan, Shamima Easmin Nishi, and Siti Nazihahasma Hassan. The authors would also like to acknowledge the USM Vice Chancellor Award (2015/2016) for financially supporting Md. Asiful Islam to pursue his Ph.D. degree.


[1] D. Bereiter, K. Hargreaves, and J. Hu, "Trigeminal mechanisms of nociception: peripheral and brainstem organization," Science of pain, vol. 5, pp. 235-460, 2008.

[2] K. M. Hargreaves, "Orofacial pain," Pain, vol. 152, no. 3, pp. S25-S32, 2011.

[3] J. T. T. de Siqueira and M. J. Teixeira, Dor orofacial: diagnostico, terapeutica e qualidade de vida, Editora Maio, 2001.

[4] P. Cascone, F. M. G. Fatone, F. Paparo, P. Arangio, and G. Iannetti, "Trigeminal impingement syndrome: The relationship between atypical trigeminal symptoms and antero-medial disk displacement," Cranio--Journal of Craniomandibular Practice, vol. 28, no. 3, pp. 177-180, 2010.

[5] D. L. Goldenberg, C. Burckhardt, and L. Crofford, "Management of fibromyalgia syndrome," Journal of the American Medical Association, vol. 292, no. 19, pp. 2388-2395, 2004.

[6] R. Benoliel, N. Birman, E. Eliav, and Y. Sharav, "The International Classification ofHeadache Disorders: Accurate diagnosis of orofacial pain?" Cephalalgia, vol. 28, no. 7, pp. 752-762,2008.

[7] J. T. Tesseroli De Siqueira, L. H. Ching, C. Nasri et al., "Clinical study of patients with persistent orofacial pain," Arquivos de Neuro-Psiquiatria, vol. 62, no. 4, pp. 988-996, 2004.

[8] A. Garven, S. Brady, S. Wood et al., "The impact of enrollment in a specialized interdisciplinary neuropathic pain clinic," Pain Research and Management, vol. 16, no. 3, pp. 159-168, 2011.

[9] I. Gilron, S. L. Booher, J. S. Rowan, B. Smoller, and M. B. Max, "A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias," Neurology, vol. 55, no. 7, pp. 964-971, 2000.

[10] H. S. Loh, S. Y. Ling, P. Shanmuhasuntharam, R. Zain, J. F. Yeo, and S. P. Khoo, "Trigeminal neuralgia. A retrospective survey of a sample of patients in Singapore and Malaysia," Australian Dental Journal, vol. 43, no. 3, pp. 188-191, 1998.

[11] P. Rasmussen, "Facial pain II. A prospective survey of 1052 patients with a view of: Character of the attacks, onset, course, and character of pain," Acta Neurochirurgica, vol. 107, no. 3-4, pp. 121-128, 1990.

[12] R. G. D. Sonuclari, "Long-term outcomes of percutaneous retrogasserian glycerol rhizotomy in 3370 patients with trigeminal neuralgia," Turkish Neurosurgery, vol. 21, no. 1, pp. 48-52, 2011.

[13] M. C. Ichida, L. Alvarenga Da Silva, M. J. Teixeira, J. T. T. De Siqueira, and S. R. D. T. De Siqueira, "Functional and sensory evaluation of patients with idiopathic trigeminal neuralgia: Comparison with controls," Clinical Neurology and Neurosurgery, vol. 130, pp. 114-121, 2015.

[14] M. Penarrocha, E. Mora, J.-V. Bagan, B. Garcia, and M. Penarrocha, "Idiopathic Trigeminal Neuropathies: A Presentation of 15 Cases," Journal ofOral and Maxillofacial Surgery, vol. 67, no. 11, pp. 2364-2368, 2009.

[15] A. M. Hegarty and J. M. Zakrzewska, "Differential diagnosis for orofacial pain, including sinusitis, TMD, trigeminal neuralgia," Dental update, vol. 38, no. 6, pp. 396-400, 2011.

[16] P. J. Jannetta, "Arterial compression of the trigeminal nerve at the pons in patients with trigeminal neuralgia. 1967," Journal of neurosurgery, vol. 107, no. 1, pp. 216-219, 2007

[17] P. J. Hamlyn and T. T. King, "Neurovascular compression in trigeminal neuralgia: A clinical and anatomical study," Journal of Neurosurgery, vol. 76, no. 6, pp. 948-954,1992.

[18] D. A. Crooks and J. B. Miles, "Trigeminal neuralgia due to vascular compression in multiple sclerosis - Post-mortem findings," British Journal of Neurosurgery, vol. 10, no. 1, pp. 85-88, 1996.

[19] K. Toda, "Etiology of Trigeminal Neuralgia," Oral Science International, vol. 4, no. 1, pp. 10-18, 2007

[20] S. Love and H. B. Coakham, "Trigeminal neuralgia: Pathology and pathogenesis," Brain, vol. 124, no. 12, pp. 2347-2360, 2001.

[21] Y. Fan, "Management of trigeminal neuralgia," Medical Bulletin, vol. 11, no. 12, pp. 3-4, 2006.

[22] N. M. H. McLeod, K. M. Tekeli, and J. Cheriyan, "Trigeminal neuralgia: assessment and management by oral and maxillofacial surgeons in the United Kingdom," British Journal of Oral and Maxillofacial Surgery, vol. 47, no. 1, pp. 42-45, 2009.

[23] F. Roncallo, I. Turtulici, G. Macchia, E. Arena, N. Bisio, and A. Bartolini, "Trigeminal neuropathy: A pictorial essay," Rivista di Neuroradiologia, vol. 12, no. 5, pp. 659-677,1999.

[24] T. J. Nurmikko and P. R. Eldridge, "Trigeminal neuralgia Pathophysiology, diagnosis and current treatment," British Journal of Anaesthesia, vol. 87, no. 1, pp. 117-132, 2001.

[25] S. Katusic, C. M. Beard, E. Bergstralh, and L. T. Kurland, "Incidence and clinical features of trigeminal neuralgia, Rochester, Minnesota, 1945-1984," Annals of Neurology, vol. 27, no. 1, pp. 89-95, 1990.

[26] J. S. H. A. Koopman, J. P. Dieleman, F. J. Huygen, M. de Mos, C. G. M. Martin, and M. C. J. M. Sturkenboom, "Incidence of facial pain in the general population," Pain, vol. 147, no. 1-3, pp. 122-127, 2009.

[27] A. Rehman, I. Abbas, S. A. Khan, E. Ahmed, F. Fatima, and S. A. Anwar, "Spectrum of trigeminal neuralgia," Journal of Ayub Medical College Abbottabad, vol. 25, no. 1-2, pp. 168-171, 2013.

[28] A. Fisher, J. M. Zakrzewska, and P. N. Patsalos, "Trigeminal neuralgia: Current treatments and future developments," Expert Opinion on EmergingDrugs, vol. 8, no. 1, pp. 123-143, 2003.

[29] D. Bahgat, D. K. Ray, A. M. Raslan, S. McCartney, and K. J. Burchiel, "Trigeminal neuralgia in young adults," Journal of Neurosurgery, vol. 114, no. 5, pp. 1306-1311, 2011.

[30] Khan, S. Khan, and U. Khitab, "Occurrence and clinical charaistics of trigeminal neuralgia: a study," Cell, vol. 300, no. 1, pp. 6-9, 2014.

[31] L. LeResche, L. A. Mancl, M. T Drangsholt, G. Huang, and M. V. Korff, "Predictors of onset of facial pain and temporomandibular disorders in early adolescence," Pain, vol. 129, no. 3, pp. 269-278, 2007.

[32] J. L. Eller, A. M. Raslan, and K. J. Burchiel, "Trigeminal neuralgia: definition and classification," Neurosurgical focus, vol. 18, no. 5, pp. 1-3, 2005.

[33] L. Bennetto, N. K. Patel, and G. Fuller, "Trigeminal neuralgia and its management," British Medical Journal, vol. 334, no. 7586, pp. 201-205, 2007

[34] A. B. O'Connor, S. R. Schwid, D. N. Herrmann, J. D. Markman, and R. H. Dworkin, "Pain associated with multiple sclerosis: systematic review and proposed classification," Pain, vol. 137, no. 1, pp. 96-111, 2008.

[35] N. Putzki, A. Pfriem, V. Limmroth et al., "Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis," European Journal of Neurology, vol. 16, no. 2, pp. 262-267, 2009.

[36] F. M. Boneschi, B. Colombo, P. Annovazzi et al., "Lifetime and actual prevalence of pain and headache in multiple sclerosis," Multiple Sclerosis, vol. 14, no. 4, pp. 514-521, 2008.

[37] W Hong, X. Zheng, Z. Wu et al., "Clinical features and surgical treatment of trigeminal neuralgia caused solely by venous compression," Acta Neurochirurgica, vol. 153, no. 5, pp. 1037-1042, 2011.

[38] G. H. Fromm and B. J. Sessle, "Pathophysiology of trigeminal neuralgia," in Trigeminal neuralgia: current concepts regarding pathogenesis and treatment, Butterworth-Heinemann, Boston, Mass, USA, 1991.

[39] T. C. Brightbill, R. S. Goodwin, and R. G. Ford, "Magnetic resonance imaging of intracranial hypotension syndrome with pathophysiological correlation," Headache, vol. 40, no. 4, pp. 292-299, 2000.

[40] D. A. Hilton, S. Love, T. Gradidge, and H. B. Coakham, "Pathological findings associated with trigeminal neuralgia caused by vascular compression," Neurosurgery, vol. 35, no. 2, pp. 299-303, 1994.

[41] M. Devor, R. Govrin-Lippmann, and Z. H. Rappaport, "Mechanism of trigeminal neuralgia: An ultrastructural analysis of trigeminal root specimens obtained during microvascular decompression surgery," Journal of Neurosurgery, vol. 96, no. 3, pp. 532-543, 2002.

[42] K. J. Burchiel, "Abnormal impulse generation in focally demyelinated trigeminal roots.," Journal of Neurosurgery, vol. 53, no. 5, pp. 674-683, 1980.

[43] Z. H. Rappaport and M. Devor, "Trigeminal neuralgia: The role of self-sustaining discharge in the trigeminal ganglion," Pain, vol. 56, no. 2, pp. 127-138,1994.

[44] A. Delitala, A. Brunori, and F. Chiappetta, "Trigeminal neuralgia resulting from infarction of the root entry zone of the trigeminal nerve: Case report," Neurosurgery, vol. 45, no. 1, pp. 199-203, 1999.

[45] T Nomura, K. Ikezaki, T Matsushima, and M. Fukui, "Trigeminal neuralgia: Differentiation between intracranial mass lesions and ordinary vascular compression as causative lesions," Neurosurgical Review, vol. 17, no. 1, pp. 51-57,1994.

[46] M. P. Sindou, M. Chiha, and P. Mertens, "Anatomical findings observed during microsurgical approaches of the cerebellopontine angle for vascular decompression in trigeminal neuralgia (350 cases)," Stereotactic and Functional Neurosurgery, vol. 63, no. 1-4, pp. 203-207, 1994.

[47] T. Hori, H. Numata, Y. Hokama, K. Muraoka, M. Takami, and Y. Saito, "Trigeminal pain caused by a parapontine epidermal cyst," Surgical Neurology, vol. 19, no. 6, pp. 517-519,1983.

[48] K. Y. Ogleznev, Y. A. Grigoryan, and K. V Slavin, "Parapontine epidermoid tumours presenting as trigeminal neuralgias: Anatomical findings and operative results," Acta Neurochirurgica, vol. 110, no. 3-4, pp. 116-119,1991.

[49] J. Yang, T. M. Simonson, A. Ruprecht, D. Meng, S. D. Vincent, and W. T C. Yuh, "Magnetic resonance imaging used to assess patients with trigeminal neuralgia," Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 81, no. 3, pp. 343-350, 1996.

[50] C. Denny E, J. Priya K, and R. Ongole, "Trigeminal neuralgia: current concepts in the medical management," World Journal of Dentistry, vol. 1, no. 1, pp. 43-46, 2010.

[51] G. Cruccu, G. Gronseth, J. Alksne et al., "AAN-EFNS guidelines on trigeminal neuralgia management," European Journal of Neurology, vol. 15, no. 10, pp. 1013-1028, 2008.

[52] R. M. Krafft, "Trigeminal neuralgia," American Family Physician, vol. 77, no. 9, pp. 1291-1296, 2008.

[53] A. Jainkittivong, V. Aneksuk, and R. P. Langlais, "Trigeminal neuralgia: A retrospective study of 188 Thai cases," Gerodontology, vol. 29, no. 2, pp. e611-e617, 2012.

[54] J. M. Zakrzewska and R. McMillan, "Trigeminal neuralgia: The diagnosis and management of this excruciating and poorly understood facial pain," Postgraduate Medical Journal, vol. 87, no. 1028, pp. 410-416, 2011.

[55] S. Katusic, D. B. Willaims, C. M. Beard, E. J. Bergstralh, and L. T. Kurland, "Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: Similarities and differences, rochester, minnesota, 1945-19841," Neuroepidemiology, vol. 10, no. 5-6, pp. 276-281,1991.

[56] A. Joffroy, M. Levivier, and N. Massager, "Trigeminal neuralgia pathophysiology and treatment," Acta Neurologica Belgica, vol. 101, no. 1, pp. 20-25, 2001.

[57] N. M. H. McLeod and D. W. Patton, "Peripheral alcohol injections in the management of trigeminal neuralgia," Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 104, no. 1, pp. 12-17, 2007

[58] Headache classification committee of the international headache society (IHS), "The international classification of headache disorders," Cephalalgia, vol. 24, no. 9, 2004.

[59] S. E. Nishi, M. Khan, S. J. Yusufzai, and N. B. Jamayet, "Tooth loss and need for replacement of teeth among adult population attending out patient department of two dental colleges in uttara, Dhaka: a cross-sectional study," International Journal of Preventive and Public Health Sciences, vol. 1, no. 1, p. 5, 2015.

[60] J. M. Zakrzewska, "Differential diagnosis of facial pain and guidelines for management," British Journal of Anaesthesia, vol. 111, no. 1, pp. 95-104, 2013.

[61] R. H. Dworkin, A. B. O'Connor, J. Audette et al., "Recommendations for the pharmacological management of neuropathic pain: an overview and literature update," Mayo Clinic Proceedings, vol. 85, no. 3, supplement, pp. S3-S14, 2010.

[62] M. Kodeeswaran, V. G. Ramesh, N. Saravanan, and R. Udesh, "Percutaneous retrogasserian glycerol rhizotomy for trigeminal neuralgia: A simple, safe, cost-effective procedure," Neurology India, vol. 63, no. 6, pp. 889-894, 2015.

[63] J. M. Zakrzewska, Trigeminal Neuralgia, WB Saunders Company, 1995.

[64] J. S. H. A. Koopman, L. M. De Vries, J. P. Dieleman, F. J. Huygen, B. H. C. Stricker, and M. C. J. M. Sturkenboom, "A nationwide study of three invasive treatments for trigeminal neuralgia," Pain, vol. 152, no. 3, pp. 507-513, 2011.

[65] J. C. Taylor, S. Brauer, and M. L. E. Espir, "Long-term treatment of trigeminal neuralgia with carbiamazepine," Postgraduate Medical Journal, vol. 57, no. 663, pp. 16-18,1981.

[66] N. Finnerup, N. Attal, S. Haroutounian et al., "Pharmacotherapy for neuropathic pain in adults: a systematic review and metaanalysis," The Lancet Neurology, vol. 14, no. 2, pp. 162-173, 2015.

[67] S. H. Sindrup and T. S. Jensen, "Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action," Pain, vol. 83, no. 3, pp. 389-400, 1999.

[68] R. Dubner, Y. Sharav, R. H. Gracely, and D. D. Price, "Idiopathic trigeminal neuralgia: sensory features and pain mechanisms," Pain, vol. 31, no. 1, pp. 23-33,1987

[69] R. Tate, L. M. Rubin, and K. C. Krajewski, "Treatment of refractory trigeminal neuralgia with intravenous phenytoin," American Journal of Health-System Pharmacy, vol. 68, no. 21, pp. 2059-2061, 2011.

[70] K. A. Baker, J. W. Taylor, and G. E. Lilly, "Treatment of trigeminal neuralgia: Use of baclofen in combination with carbamazepine," Clinical Pharmacy, vol. 4, no. 1, pp. 93-96,1985.

[71] P. J. Wiffen, S. Collins, H. McQuay, D. Carroll, A. Jadad, and A. Moore, "Anticonvulsant drugs for acute and chronic pain," Cochrane Database of Systematic Reviews, no. 3, Article ID CD001133, 2005.

[72] G. Lunardi, M. Leandri, C. Albano et al., "Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia," Neurology, vol. 48, no. 6, pp. 1714-1717, 1997.

[73] S. Shaikh, H. B. Yaacob, and R. B. Abd Rahman, "Lamotrigine for trigeminal neuralgia: Efficacy and safety in comparison with carbamazepine," Journal ofthe Chinese Medical Association, vol. 74, no. 6, pp. 243-249, 2011.

[74] T. Sist, V. Filadora, M. Miner, and M. Lema, "Gabapentin for idiopathic trigeminal neuralgia: Report of two cases," Neurology, vol. 48, no. 5, p. 1467,1997

[75] C. K. Pandey, N. Singh, and P. K. Singh, "Gabapentin for refractory idiopathic trigeminal neuralgia," Journal ofthe Indian Medical Association, vol. 106, no. 2, pp. 124-125, 2008.

[76] J. M. Zakrzewska and P. N. Patsalos, "Drugs used in the management of trigeminal neuralgia," Oral Surgery, Oral Medicine, Oral Pathology, vol. 74, no. 4, pp. 439-450,1992.

[77] E. Spina and G. Perugi, "Antiepileptic drugs: Indications other than epilepsy," Epileptic Disorders, vol. 6, no. 2, pp. 57-75,2004.

[78] T. P. Jorns and J. M. Zakrzewska, "Evidence-based approach to the medical management of trigeminal neuralgia," British Journal of Neurosurgery, vol. 21, no. 3, pp. 253-261, 2007

[79] A. Ariyawardana, R. Pallegama, M. Sitheeque, and A. Ranasinghe, "Use of single-and multi-drug regimens in the management of classic (idiopathic) trigeminal neuralgia: an 11-year experience at a single Sri Lankan institution," Journal of investigative and clinical dentistry, vol. 3, no. 2, pp. 98-102, 2012.

[80] F. G. Barker II, P. J. Jannetta, D. J. Bissonette, M. V. Larkins, and H. D. Jho, "The long-term outcome of microvascular decompression for trigeminal neuralgia," New England Journal of Medicine, vol. 334, no. 17, pp. 1077-1083,1996.

[81] J. M. Taha and J. Tew J.M., "Treatment of trigeminal neuralgia by percutaneous radiofrequency rhizotomy," Neurosurgery Clinics of North America, vol. 8, no. 1, pp. 31-39,1997

[82] D. A. Sun, L. Martin, and C. R. Honey, "Percutaneous radio-frequency trigeminal rhizotomy in a patient with an implanted cardiac pacemaker," Anesthesia and Analgesia, vol. 99, no. 6, pp. 1585-1586, 2004.

[83] S. S. Saini, "Reterogasserian anhydrous glycerol injection therapy in trigeminal neuralgia: observations in 552 patients," Journal of Neurology, Neurosurgery and Psychiatry, vol. 50, no. 11, pp. 1536-1538,1987.

[84] D. Kondziolka and L. D. Lunsford, "Percutaneous retrogasserian glycerol rhizotomy for trigeminal neuralgia: technique and expectations," Neurosurgical Focus, vol. 18, no. 5, pp. 1-4, 2005.

[85] M. Mizuno, K. Saito, M. Takayasu, and J. Yoshida, "Percutaneous microcompression of the trigeminal ganglion for elderly patients with trigeminal neuralgia and patients with atypical trigeminal neuralgia," Neurologia Medico-Chirurgica, vol. 40, no. 7, pp. 347-351, 2000.

[86] M. J. Fardy, J. M. Zakrzewska, and D. W. Patton, "Peripheral surgical techniques for the management of trigeminal neuralgiaAlcohol and glycerol injections," Acta Neurochirurgica, vol. 129, no. 3-4, pp. 181-184, 1994.

[87] W. C. Ngeow and R. Nair, "Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain," Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 109, no. 3, pp. e47-e50, 2010.

[88] H. M. B. Lunde, 0. Torkildsen, L. B0, and A. K. Bertelsen, "Botulinum Toxin as Monotherapy in Symptomatic Trigeminal Neuralgia," Headache, vol. 56, no. 6, pp. 1035-1039, 2016.

[89] J. M. Zakrzewska and F. F. Nally, "The role of cryotherapy (cryoanalgesia) in the management of paroxysmal trigeminal neuralgia: A six year experience," British Journal of Oral and Maxillofacial Surgery, vol. 26, no. 1, pp. 18-25, 1988.

[90] G. Gronseth, G. Cruccu, J. Alksne et al., "Practice Parameter: The diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies," Neurology, vol. 71, no. 15, pp. 1183-1190, 2008.

[91] N. E. Martinez Moreno, J. Gutierrez-Sarraga, G. Rey-Portoles, and R. M. ?Alvarez, "Long-Term Outcomes in the Treatment of Classical Trigeminal Neuralgia by Gamma Knife Radiosurgery: A Retrospective Study in Patients With Minimum 2-Year Follow-up," Neurosurgery, 2016.

[92] W. Pradel, M. Hlawitschka, U. Eckelt, R. Herzog, and K. Koch, "Cryosurgical treatment of genuine trigeminal neuralgia," British Journal of Oral and Maxillofacial Surgery, vol. 40, no. 3, pp. 244-247, 2002.

[93] Z. Sarsam, M. Garcia-Fiana, T. J. Nurmikko, T R. K. Varma, and P Eldridge, "The long-term outcome of microvascular decompression for trigeminal neuralgia," British Journal of Neurosurgery, vol. 24, no. 1, pp. 18-25, 2010.

[94] J. Regis, P Metellus, M. Hayashi, P Roussel, A. Donnet, and F. Bille-Turc, "Prospective controlled trial of gamma knife surgery for essential trigeminal neuralgia," Journal of Neurosurgery, vol. 104, no. 6, pp. 913-924, 2006.

[95] R. A. Egan, M. Pless, and W. T. Shults, "Monocular blindness as a complication of trigeminal radiofrequency rhizotomy," American Journal of Ophthalmology, vol. 131, no. 2, pp. 237-240, 2001.

[96] Y. Kanpolat, A. Savas, A. Bekar, and C. Berk, "Percutaneous controlled radiofrequency trigeminal rhizotomy for the treatment of idiopathic trigeminal neuralgia: 25-year experience with 1600 patients," Neurosurgery, vol. 48, no. 3, pp. 524-534, 2001.

[97] C. S. Greene, "The etiology of temporomandibular disorders: implications for treatment," Journal of Oral & Facial Pain and Headache, vol. 15, no. 2, pp. 93-105, 2001.

[98] D. G. Simons, "Review of enigmatic MTrPs as a common cause of enigmatic musculoskeletal pain and dysfunction," Journal of Electromyography and Kinesiology, vol. 14, no. 1, pp. 95-107, 2004.

[99] J. G. Travell and D. G. Simons, Myofascial Pain And Dysfunction: The Trigger Point Manual, Lippincott Williams & Wilkins, 1992.

[100] R. A. Moss, J. Garrett, and J. F. Chiodo, "Temporomandibular joint dysfunction and myofascial pain dysfunction syndromes: Parameters, etiology, and treatment," Psychological Bulletin, vol. 92, no. 2, pp. 331-346,1982.

[101] J. Z. Srbely, "New trends in the treatment and management of myofascial pain syndrome," Current Pain and Headache Reports, vol. 14, no. 5, pp. 346-352, 2010.

[102] P Svensson and T Graven-Nielsen, "Craniofacial Muscle Pain: Review of Mechanisms and Clinical Manifestations," Journal of Orofacial Pain, vol. 15, no. 2, pp. 117-145, 2001.

[103] D. M. Laskin and S. Block, "Diagnosis and treatment of myofacial pain-dysfunction (MPD) syndrome," The Journal of Prosthetic Dentistry, vol. 56, no. 1, pp. 75-84,1986.

[104] C. H. Wilkes, "Internal derangements of the temporomandibular joint: pathological variations," Archives of Otolaryngology--Head and Neck Surgery, vol. 115, no. 4, pp. 469-477,1989.

[105] J. G. Travell and D. G. Simons, Myofascial pain and dysfunction: the trigger point manual, vol. 2 of The lower extremities, Williams & Wilkins, 1999.

[106] P. Marchettini, "Muscle pain: Animal and human experimental and clinical studies," Muscle & Nerve, vol. 16, no. 10, pp. 1033-1039, 1993.

[107] M. Cummings and P Baldry, "Regional myofascial pain: diagnosis and management," Best Practice and Research: Clinical Rheumatology, vol. 21, no. 2, pp. 367-387, 2007

[108] J. Borg-Stein and D. G. Simons, "Focused review: myofascial pain," Archives of Physical Medicine and Rehabilitation, vol. 83, supplement 1, no. 3, pp. S40-S47, 2002.

[109] K. G. Henriksson, E. Backman, C. Henriksson, and J. H. De Laval, "Chronic regional muscular pain in women with precise manipulation work. A study of pain characteristics, muscle function, and impact on daily activities," Scandinavian Journal of Rheumatology, vol. 25, no. 4, pp. 213-223,1996.

[110] A. H. Wheeler, "Myofascial Pain Disorders: Theory to Therapy," Drugs, vol. 64, no. 1, pp. 45-62, 2004.

[111] J. R. Fricton, R. Kroening, D. Haley, and R. Siegert, "Myofascial pain syndrome of the head and neck: a review of clinical characteristics of 164 patients," Oral Surgery Oral Medicine and Oral Pathology, vol. 60, no. 6, pp. 615-623,1985.

[112] R. Gerwin, "A study of 96 subjects examined both for fibromyalgia and myofascial pain," Journal Musculoskeletal Pain, vol. 3, supplement 1, p. 121, 1995.

[113] Drewes and P Jennum, "Epidemiology of myofascial pain, low back pain, morning stiffness and sleep-related complaints in the general population," Journal Musculoskeletal Pain, vol. 3, supplement 1, p. 68, 1995.

[114] D. A. Fishbain, M. Goldberg, B. Robert Meagher, R. Steele, and H. Rosomoff, "Male and female chronic pain patients categorized by DSM-III psychiatric diagnostic criteria," Pain, vol. 26, no. 2, pp. 181-197, 1986.

[115] G. Carlsson, T. Magnusson, and A. Wedel, "Survey of patients seen at a department of Stomatognathic Physiology," Swedish Dental Journal, vol. 69, p. 115,1976.

[116] M. A. Giamberardino, G. Affaitati, A. Fabrizio, and R. Costantini, "Myofascial pain syndromes and their evaluation," Best Practice and Research: Clinical Rheumatology, vol. 25, no. 2, pp. 185-198, 2011.

[117] C. Couppe, A. Midttun, J. Hilden, U. J0rgensen, P Oxholm, and A. Fuglsang-Frederiksen, "Spontaneous needle electromyographic activity in myofascial trigger points in the infraspinatus muscle: a blinded assessment," Journal of Musculoskeletal Pain, vol. 9, no. 3, pp. 7-16, 2001.

[118] Pongratz and M. Spath, "Morphologic aspects of muscle pain syndromes: a critical review," Physical Medicine and Rehabilitation Clinics of North America, vol. 8, pp. 55-68,1997.

[119] P Baldry, M. B. Yunus, and F. Inanici, "Myofascial pain and fibromyalgia syndromes: a clinical guide to diagnosis and management," Elsevier Health Sciences, 2001.

[120] S. Mense, D. Simons, and I. Russell, Muscle pain. Understanding its nature, diagnosis, and treatment, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2001.

[121] L. Bendtsen, R. Jensen, and J. Olesen, "Qualitatively altered nociception in chronic myofascial pain," Pain, vol. 65, no. 2-3, pp. 259-264,1996.

[122] D. R. Hubbard and G. M. Berkoff, "Myofascial trigger points show spontaneous needle EMG activity," Spine, vol. 18, no. 13, pp. 1803-1807,1993.

[123] C.-Z. Hong and D. G. Simons, "Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points," Archives of Physical Medicine and Rehabilitation, vol. 79, no. 7, pp. 863-872, 1998.

[124] J. P Okeson, Management of Temporomandibular Disorders and Occlusion, Elsevier Health Sciences, 2014.

[125] C. J. Manheim, The myofascial release manual, Slack Incorporated, 2008.

[126] E. Winocur, A. Gavish, A. Emodi-Perlman, M. Halachmi, and I. Eli, "Hypnorelaxation as treatment for myofascial pain disorder: A comparative study," Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics, vol. 93, no. 4, pp. 429-434, 2002.

[127] S. Ingawale and T. Goswami, "Temporomandibular joint: Disorders, treatments, and biomechanics," Annals of Biomedical Engineering, vol. 37, no. 5, pp. 976-996, 2009.

[128] A. Kamanli, A. Kaya, O. Ardicoglu, S. Ozgocmen, F. O. Zengin, and Y. Bayik, "Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome," Rheumatology International, vol. 25, no. 8, pp. 604-611, 2005.

[129] S. Ay, D. Evcik, and B. S. Tur, "Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial," Clinical Rheumatology, vol. 29, no. 1, pp. 19-23, 2010.

[130] K.-Y. Ho and K.-H. Tan, "Botulinum toxin A for myofascial trigger point injection: A qualitative systematic review," European Journal of Pain, vol. 11, no. 5, pp. 519-527, 2007

[131] L. Kalichman and S. Vulfsons, "Dry needling in the management of musculoskeletal pain," Journal of the American Board of Family Medicine, vol. 23, no. 5, pp. 640-646, 2010.

[132] N. A. Scott, B. Guo, P M. Barton, and R. D. Gerwin, "Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review," Pain Medicine, vol. 10, no. 1, pp. 54-69, 2009.

[133] M. C. B. Gazi, A. M. Issy, I. P ?Avila, and R. K. Sakata, "Comparison of Acupuncture to Injection for Myofascial Trigger Point Pain," Pain Practice, vol. 11, no. 2, pp. 132-138, 2011.

[134] J. Z. Srbely, J. P Dickey, M. Lowerison, A. M. Edwards, P S. Nolet, and L. L. Wong, "Stimulation of myofascial trigger points with ultrasound induces segmental antinociceptive effects: A randomized controlled study," Pain, vol. 139, no. 2, pp. 260-266, 2008.

[135] T. Dao and G. J. Lavigne, "Oral splints: the crutches for temporomandibular disorders and bruxism," Critical Reviews in Oral Biology and Medicine, vol. 9, no. 3, pp. 345-361,1998.

[136] A. Michelotti, G. Iodice, S. Vollaro, M. H. Steenks, and M. Farella, "Evaluation ofthe short-term effectiveness ofeducation versus an occlusal splint for the treatment of myofascial pain of the jaw muscles," Journal of the American Dental Association, vol. 143, no. 1, pp. 47-53, 2012.

[137] R. S. S. Silva, P C. Conti, J. R. Lauris, R. O. da Silva, and L. F. Pegoraro, "Pressure pain threshold in the detection of masticatory myofascial pain: an algometer-based study," Journal of Orofacial Pain, vol. 19, no. 4, pp. 318-324, 2005.

[138] T. T. T. Dao, G. J. Lavigne, A. Charbonneau, J. S. Feine, and J. P. Lund, "The efficacy of oral splints in the treatment of myofascial pain of the jaw muscles: a controlled clinical trial," Pain, vol. 56, no. 1, pp. 85-94, 1994.

[139] D. J. Alvarez and P G. Rockwell, "Trigger points: diagnosis and management," American Family Physician, vol. 65, no. 4, pp. 653-660, 2002.

[140] M. S. Medlicott and S. R. Harris, "A systematic review of the effectiveness of exercise, manual therapy, electrotherapy, relaxation training, and biofeedback in the management of temporomandibular disorder," Physical Therapy, vol. 86, no. 7, pp. 955-973, 2006.

[141] E. Yap, "Myofascial pain--An overview," Annals Academy of Medicine Singapore, vol. 36, no. 1, pp. 43-48, 2007.

[142] K. J. Burchiel, "Editorial: Glossopharyngeal neuralgia," Journal of Neurosurgery, vol. 115, no. 5, pp. 934-935, 2011.

[143] D. M. Patel, E. Besson, P Schmalz, J. H. Miller, and W. S. F. Iii, "Chapter 5--glossopharyngeal neuralgia treatment a2--tubbs, R. Shane," in Nerves and Nerve Injuries, E. Rizk, M. M. Shoja, M. Loukas, N. Barbaro, and R. J. Spinner, Eds., pp. 71-80, Academic Press, San Diego, CA, USA.

[144] A. Minagar and W. A. Sheremata, "Glossopharyngeal neuralgia and MS," Neurology, vol. 54, no. 6, pp. 1368-1370, 2000.

[145] R. Rey-Dios and A. A. Cohen-Gadol, "Current neurosurgical management of glossopharyngeal neuralgia and technical nuances for microvascular decompression surgery," Neurosurgical Focus, vol. 34, no. 3, article no. E8, 2013.

[146] A. R. Stogicza and A. M. Trescot, "Glossopharyngeal nerve entrapment," in Peripheral Nerve Entrapments, pp. 241-250, Springer, 2016.

[147] P M. Singh, M. Kaur, and A. Trikha, "An uncommonly common: Glossopharyngeal neuralgia," Annals of Indian Academy of Neurology, vol. 16, no. 1, pp. 1-8, 2013.

[148] M. J. Teixeira, S. R. D. T. De Siqueira, and E. Bor-Seng-Shu, "Glossopharyngeal neuralgia: Neurosurgical treatment and differential diagnosis," Acta Neurochirurgica, vol. 150, no. 5, pp. 471-475, 2008.

[149] O. Hamada, T. Ogata, H. Abe et al., "A patient with vertebral artery dissection who initially suffered from pharyngeal pain," Neurological Surgery, vol. 41, no. 12, pp. 1081-1085, 2013.

[150] M. Sindou and J. Chen, "Treatment of vagoglossopharyngeal neuralgia with MVD and other neurosurgical procedures," in Microvascular Decompression Surgery, pp. 137-150, Springer, 2016.

[151] P Ferroli, A. Fioravanti, M. Schiariti et al., "Microvascular decompression for glossopharyngeal neuralgia: A long-term retrospectic review of the Milan-Bologna experience in 31 consecutive cases," Acta Neurochirurgica, vol. 151, no. 10, pp. 1245-1250, 2009.

[152] C. Webb, Z. Makura, and M. McCormick, "Glossopharyngeal neuralgia following foreign body impaction in the neck," Journal of Laryngology and Otology, vol. 114, no. 1, pp. 70-72, 2000.

[153] R. Benoliel and E. Eliav, "Neuropathic Orofacial Pain," Oral and Maxillofacial Surgery Clinics of North America, vol. 20, no. 2, pp. 237-254, 2008.

[154] T J. Nurmikko, "Chapter 38 Trigeminal neuralgia and other facial neuralgias," Handbook of Clinical Neurology, vol. 81, pp. 573-596, 2006.

[155] H. Kobata, A. Kondo, K. Iwasaki, and T Nishioka, "Combined hyperactive dysfunction syndrome of the cranial nerves: Trigeminal neuralgia, hemifacial spasm, and glossopharyngeal

neuralgia: 11- Year experience and review," Neurosurgery, vol. 43, no. 6, pp. 1351-1362,1998.

[156] M. Romero-Reyes and J. M. Uyanik, "Orofacial pain management: current perspectives," Journal of Pain Research, vol. 21, no. 7, pp. 99-115, 2014.

[157] M. Ozenci, R. Karaoguz, C. Conkbayir, T. Altin, and Y. Kanpolat, "Glossopharyngeal neuralgia with cardiac syncope treated by glossopharyngeal rhizotomy and microscular decompression," Europace, vol. 5, no. 2, pp. 149-152, 2003.

[158] S. G. Kapnadak, I. Mikolaenko, K. Enfield, D. R. Gress, and B. R. Nathan, "Ondine's Curse with accompanying trigeminal and glossopharyngeal neuralgia secondary to medullary telangiectasia," Neurocritical Care, vol. 12, no. 3, pp. 395-399, 2010.

[159] A.-M. Childs, J. F. Meaney, C. D. Ferrie, and P. C. Holland, "Neurovascular compression of the trigeminal and glossopharyngeal nerve: Three case reports," Archives of Disease in Childhood, vol. 82, no. 4, pp. 311-315, 2000.

[160] J. M. S. Pearce, "Glossopharyngeal neuralgia," European Neurology, vol. 55, no. 1, pp. 49-52, 2006.

[161] M. Sindou, Y. Keravel, and B. Laurent, "Aspects cliniques et therapeutiques des nevralgies essentielles du trijumeau et du glossopharyngien," EMC--Neurologie, vol. 11, no. 2, pp. 1-21, 2014.

[162] A. Patel, A. Kassam, M. Horowitz, and Y.-F. Chang, "Microvascular decompression in the management of glossopharyngeal neuralgia: analysis of 217 cases," Neurosurgery, vol. 50, no. 4, pp. 705-711, 2002.

[163] H. Karibe, R. Shirane, and T. Yoshimoto, "Preoperative visualization of microvascular compression of cranial nerve IX using constructive interference in steady state magnetic resonance imaging in glossopharyngeal neuralgia," Journal of Clinical Neuroscience, vol. 11, no. 6, pp. 679-681, 2004.

[164] F Fischbach, T. N. Lehmann, J. Ricke, and H. Bruhn, "Vascular compression in glossopharyngeal neuralgia: Demonstration by high-resolution MRI at 3 tesla," Neuroradiology, vol. 45, no. 11, pp. 810-811, 2003.

[165] C. Gaul, P. Hastreiter, A. Duncker, and R. Naraghi, "Diagnosis and neurosurgical treatment of glossopharyngeal neuralgia: Clinical findings and 3-D visualization of neurovascular compression in 19 consecutive patients," Journal of Headache and Pain, vol. 12, no. 5, pp. 527-534, 2011.

[166] M. Kawashima, T. Matsushima, T. Inoue, T. Mineta, J. Masuoka, and N. Hirakawa, "Microvascular decompression for glossopharyngeal neuralgia through the transcondylar fossa (supracondylar transjugular tubercle) approach," Operative Neurosurgery, vol. 66, no. 6, pp. 275-280, 2010.

[167] A. Hiwatashi, T. Matsushima, T. Yoshiura et al., "MRI of glossopharyngeal neuralgia caused by neurovascular compression," American Journal of Roentgenology, vol. 191, no. 2, pp. 578-581, 2008.

[168] Foczpanska-Setta, M. Split, and W. Split, "Radiological evaluation of elongated styloid process," Polski Merkuriusz Lekarski: organ Polskiego Towarzystwa Lekarskiego, vol. 29, no. 171, pp. 194-197, 2010.

[169] N. B. Finnerup, S. H. Sindrup, and T. S. Jensen, "The evidence for pharmacological treatment of neuropathic pain," Pain, vol. 150, no. 3, pp. 573-581, 2010.

[170] M. Yang, M. Zhou, L. He, N. Chen, and J. M. Zakrzewska, "Non-antiepileptic drugs for trigeminal neuralgia," Cochrane Library, 2011.

[171] R. H. Dworkin, M. Backonja, M. C. Rowbotham et al., "Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations," Archives of Neurology, vol. 60, no. 11, pp. 1524-1534, 2003.

[172] M. A. Cosgrove, D. K. Towns, G. J. Fanciullo, and A. D. Kaye, "Interventional pain management," Essentials of Pain Management, pp. 237-299, 2011.

[173] P. M. Singh, M. Dehran, V K. Mohan, A. Trikha, and M. Kaur, "Analgesic efficacy and safety of medical therapy alone vs combined medical therapy and extraoral glossopharyngeal nerve block in glossopharyngeal neuralgia," Pain Medicine, vol. 14, no. 1, pp. 93-102, 2013.

[174] M. Romanoff, "Somatic nerve blocks of the head and neck," in Practical Management of Pain, 596, p. 579, St Louis, Mo: Mosby, 3rd edition, 2000.

[175] S. R. Kandan, S. Khan, D. S. Jeyaretna, S. Lhatoo, N. K. Patel, and H. B. Coakham, "Neuralgia of the glossopharyngeal and vagal nerves: Long-term outcome following surgical treatment and literature review," British Journal of Neurosurgery, vol. 24, no. 4, pp. 441-446, 2010.

[176] M. Stevens and B. Onofrio, "Glossopharyngeal rhizotomy for glossopharyngeal neuralgia," in Neurosurgical Operative Atlas: Functional neurosurgery Stuttgart, pp. 127-130, Thieme Medical Publishers, Germany, 2008.

[177] S. B. Graff-Radford, A. Newman, and A. Ananda, "Treatment options for glossopharyngeal neuralgia," Therapy, vol. 2, no. 5, pp. 733-737, 2005.

[178] M. N. Piagkou, S. Anagnostopoulou, K. Kouladouros, and G. Piagkos, "Eagle's syndrome: A review of the literature," Clinical Anatomy, vol. 22, no. 5, pp. 545-558, 2009.

[179] R. V Shah and G. B. Racz, "Pulsed mode radiofrequency lesioning to treat chronic post-tonsillectomy pain (secondary glossopharyngeal neuralgia)," Pain Practice, vol. 3, no. 3, pp. 232-237, 2003.

Mohammad Khan, (1) Shamima Easmin Nishi, (2) Siti Nazihahasma Hassan, (3) Md. Asiful Islam, (4) and Siew Hua Gan (4)

(1) Community Medicine, School of Dental Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

(2) Orthodontic Unit, School of Dental Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

(3) Hematology, School of Dental Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

(4) Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia

Correspondence should be addressed to Mohammad Khan; and Siew Hua Gan;

Received 5 February 2017; Revised 12 April 2017; Accepted 24 April 2017; Published 30 July 2017

Academic Editor: Francesca A. Bianchi

Caption: FIGURE 1: The basic diagnostic criteria of trigeminal neuralgia (TN).

Caption: FIGURE 2: Commonly used diagnostic tools and features of myofascial pain dysfunction syndrome (MPDS).
TABLE 1: Characteristics and management of trigeminal neuralgia
in the maxillofacial region.

Diseases      Clinical          Pharmaco        Side effects
              features          -logical

Trigeminal    Pain, electric    Carbamazepine   (i) Development
  neuralgia     shock like                        of resistance
              Pain                                and intolerance
                duration,                       (ii) Dizziness
                seconds                         (iii) Nausea
              Intensity,                        (iv) Ataxia
                severe                          (v) Vomiting
              Localization,                     (vi) Xerostomia
                good Characte   Oxcarbazepine   (i) Dizziness
                -ristics,                       (ii) Fatigue
                trigger zone,                   (iii) Nausea
                diurnal                         (iv) Vomiting
              Trigger points,                   (v) Headache
                nonnoxious                      (vi) Acne
                stimulus                        (vii) Dry mouth
                                Gabapentin      (i) Dizziness
                                                (ii) Fatigue
                                                (iii) weight gain
                                                (iv) Drowsiness
                                                (v) peripheral
                                Pregabalin      (i) Dizziness
                                                (ii) Blurred vision
                                                (iii) Diplopia
                                                (iv) Increased
                                                  appetite and
                                                  weight gain
                                                (v) Euphoria,
                                                  and vivid
                                                (vi) Changes
                                                  in libido
                                                  (increase or
                                                (vii) Memory
                                                (viii) Tremors
                                                (ix) Dry mouth
                                                (x) Erectile
                                                (xi) Peripheral
                                                (xii) Nasophary
                                                (xiii) Increased
                                                  kinase level
                                Topiramate      (i) Paresthesia
                                                (ii) Nausea
                                                (iii) Lack of
                                                (iv) Diplopia
                                                (v) Nervousness
                                                  and dizziness
                                                (vi) Memory
                                                (vii) Speech
                                                (viii) Disturbance
                                                (ix) Diarrhea
                                Valproates      (i) Skin rash
                                                (ii) Hair loss
                                                (iii) Weight gain
                                Tricyclic       (i) Sedation
                                  antidepres    (ii) Dry mouth
                                  -sants        (iii) Blurred
                                  (TCA)           vision
                                                (iv) Breast
                                                  enlargement in
                                                (v) Constipation,
                                                (vi) Weight gain
                                                (vii) High blood
                                                  glucose level
                                Sedatives (on   (i) Apnea
                                  condition)    (ii) Physical
                                                (iii) Decreased
                                                  mean arterial
                                                (iv) Tachycardia
                                                (v) Paradoxical

Diseases      Clinical          Pharmaco        Surgical/local
              features          -logical        treatments

Trigeminal    Pain, electric    Carbamazepine   Percutaneous
  neuralgia     shock like                        trigeminal
              Pain                                rhizotomy
                duration,       Oxcarbazepine   Ablative
                seconds                           peripheral
              Intensity,                          procedures
                severe                            (neurectomy)
              Localization,     Gabapentin
                good Characte   Pregabalin      Microvascular
                -ristics,                         decompression
                trigger zone,   Topiramate      Gamma knife
                diurnal                           radiosurgery
              Trigger points,   Valproates      Myotherapy
                nonnoxious      Tricyclic       Injections
                stimulus          antidepres
                                Sedatives (on   Acupuncture
                                  condition)    Therapeutic

Diseases      Clinical          Pharmaco        Limitation
              features          -logical

Trigeminal    Pain, electric    Carbamazepine   (i) Recurrence
  neuralgia     shock like                        of pain
              Pain                              (ii) Dysesthesia
                duration,                         (troublesome
                seconds                           numbness)
              Intensity,                        (iii) Loss of
                severe                            corneal reflex
              Localization,     Oxcarbazepine   (i) Less
                good Characte                     morbidity
                -ristics,                         but with
                trigger zone,                     chance of
                diurnal                           recurrence
              Trigger points,   Gabapentin
                nonnoxious      Pregabalin      (i) Low
                stimulus                          recurrence
                                                  of pain
                                                (ii) Chance
                                                  of causing
                                                  nerve damage
                                                (iii) Haring
                                                  loss, double
                                                  vision, facial
                                                  numbness, or
                                Topiramate      (i) Tenderness
                                                  where the
                                                  screws or
                                                  pins were
                                                (ii) Hair loss
                                                  where the
                                                  was directed
                                                (iii) Damage
                                                  to surrounding
                                                  tissues in
                                                  the brain,
                                                  caused by
                                Valproates      (i) Regular
                                                  monitoring is
                                                  not possible
                                Tricyclic       (i) As it is a
                                  antidepres      painful
                                  -sants          procedure,
                                  (TCA)           the patient
                                                  feels uncomfor
                                                  -table during
                                Sedatives (on   (i) Painful
                                  condition)      procedure
                                                (i) A skilled
                                                  person is
                                                  needed, and
                                                  the patient
                                                  is still

TABLE 2: Characteristics and management of myofascial
pain dysfunction syndrome in the maxillofacial region.

Diseases        Clinical         Pharmacological   Side effects
                features         treatments

Myofascial      Pain, dull and   Nonsteroidal      (i) Indigestion
  pain            aching type      anti-inflam     (ii) Stomach
  dysfunction   Pain duration,     -matory drug      upset
  syndrome        constant                         (iii) Stomach
                Intensity,                           bleeding
                  moderate                         (iv) Peptic
                Localization,                        ulcer
                  diffuse                          (v) Fluid
                Characte                             retention
                  -ristics,      Tricyclic         (As stated in
                  generalized,     antidepres        Table 1)
                  spontaneous      -sants (TCA)
                Trigger point,   Sedatives         (i) Apnea
                  palpation,       (on condi       (ii) Decreased
                  function         -tion)            mean arterial
                                                   (iv) Paradoxical

Diseases        Clinical         Pharmacological   Surgical/
                features         treatments        local

Myofascial      Pain, dull and   Nonsteroidal      Psychotherapy
  pain            aching type      anti-inflam
  dysfunction   Pain duration,     -matory drug
  syndrome        constant       Tricyclic         Myotherapy
                Intensity,         antidepres      Injections
                  moderate         -sants (TCA)
                Localization,    Sedatives         Acupuncture
                  diffuse          (on condi       Therapeutic
                Characte           -tion)            ultrasound
                Trigger point,

Diseases        Clinical         Pharmacological   Limitation
                features         treatments

Myofascial      Pain, dull and   Nonsteroidal      (i) Failure of
  pain            aching type      anti-inflam       episodic
  dysfunction   Pain duration,     -matory drug      counseling
  syndrome        constant                           and patient's
                Intensity,                           ignorance
                  moderate       Tricyclic         (i) Regular
                Localization,      antidepres        monitoring is
                  diffuse          -sants (TCA)      not possible
                Characte                           (i) As it is a
                  -ristics,                          painful
                  generalized,                       procedure,
                  spontaneous                        the patient
                Trigger point,                       feels uncomfor
                  palpation,                         -table during
                  function                           injection
                                 Sedatives         (i) Painful
                                   (on condi         procedure
                                   -tion)          (i) A skilled
                                                     person is
                                                     needed, and
                                                     the patient
                                                     is still

TABLE 3: Characteristics and management of glossopharyngeal
neuralgia in the maxillofacial region.

Diseases       Clinical         Pharmacological   Surgical/local
               features         treatments        treatments

Glossop        Pain, dull       Carbarn azepine   GN nerve block
  -haryngeal     type                             Myotherapy
  neuralgia    Pain                               Percutaneous
                 duration,                          radiofrequency
                 short                              thermal
                 duration                           rhizotomy
               Intensity,       Gabapentin        Injections
                 mild to          pregabalin      Direct section
                 moderate                           of the nerve
               Localization,                        in the cerebe
                 diffuse                            -llopontine
               Characte                             angle
                 -ristics,      Sedatives         Microvascular
                 usually          (on               decompression
                 pain in          condition)
                 the throat
                 /mouth floor

Diseases       Clinical         Pharmacological   Limitation
               features         treatments

Glossop        Pain, dull       Carbarn azepine   (i) Chance of
  -haryngeal     type                               trauma to the
  neuralgia    Pain                                 internal jugular
                 duration,                          vein and carotid
                 short                              artery
                 duration                         (ii) Hematoma
               Intensity,                           formation
                 mild to                          (i) Regular
                 moderate                           monitoring is
               Localization,                        not possible
                 diffuse                          (ii) Recurrence
               Characte                           (iii) Hoarseness
                 -ristics,                          of voice
                 usually                          (iv) Vocal cord
                 pain in                            paralysis, and
                 the throat                         dysphagia
                 /mouth floor                       (difficulty in
               Trigger                              swallowing)
                 point,         Gabapentin        (i) As it is a
                 swallowing       pregabalin        painful
                                                    the patient
                                                    feels uncom
                                                  (i) High
                                                    with neurologic
                                                    and life
                                                  (ii) Thrombo
                                                  (iii) Meningitis
                                                  (iv) Cerebrospinal
                                                    fluid leak,
                                                  (v) Cutaneous
                                                    flap distension
                                                  (vi) Facial nerve
                                                  (vii) Ocular
                                                  (viii) Tinnitus
                                Sedatives         (i) Low recurrence
                                  (on               of pain
                                  condition)      (ii) Chance of
                                                    nerve damage
                                                  (iii) Hoarseness
                                                  (iv) Difficulty
                                                  (v) Unsteady gait

TABLE 4: Radiological criteria in the diagnosis
of TN, MPDS, and GPN.

Diseases   Imaging (CT/MRI)

TN         Vascular compression of the trigeminal nerve
             (root entry zone) (demyelination and
           MS plaque (dorsal root entry zone)
           Trigeminal ganglion (degenerative
             hypermyelination and microneuromata)
MPDS       Condyle and disc position of TMJ
GPN        Vascular compression of the glossopharyngeal
             nerve (root entry zone)
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Khan, Mohammad; Nishi, Shamima Easmin; Hassan, Siti Nazihahasma; Islam, Md. Asiful; Gan, Siew Hua
Publication:Pain Research and Management
Article Type:Disease/Disorder overview
Date:Jan 1, 2017
Previous Article:Neural Mobilization Treatment Decreases Glial Cells and Brain-Derived Neurotrophic Factor Expression in the Central Nervous System in Rats with...
Next Article:Patient Perception of Acute Pain Management: Data from Three Tertiary Care Hospitals.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters